Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 86,600 shares, an increase of 50.9% from the December 15th total of 57,400 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average trading volume of 50,200 shares, the days-to-cover ratio is currently 1.7 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Stock Performance

Shares of NASDAQ:DARE traded up $0.01 during trading hours on Friday, hitting $3.34. The stock had a trading volume of 11,893 shares, compared to its average volume of 22,963. The stock’s fifty day simple moving average is $3.30 and its 200 day simple moving average is $3.42. The firm has a market capitalization of $29.06 million, a price-to-earnings ratio of -5.65 and a beta of 1.28. Daré Bioscience has a 1-year low of $2.67 and a 1-year high of $7.56.

Institutional Trading of Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC grew its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.